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Click to hear Dr Baglin’s perspective on the role of the
laboratory in treatment with new oral anticoagulants
Summary. One of the key benefits of the direct oral anti-
coagulants (DOACs) is that they do not require routine
laboratory monitoring. Nevertheless, assessment of
DOAC exposure and anticoagulant effects may become
useful in various clinical scenarios. The five approved
DOACs (apixaban, betrixaban, dabigatran etexilate,
edoxaban and rivaroxaban) have different characteristics
impacting assay selection and the interpretation of results.
This article provides an updated overview on (i) which
test to use (and their advantages and limitations), (ii)
when to assay DOAC levels, (iii) how to interpret the
results relating to bleeding risk, emergency situations and
perioperative management, and (iv) what is the impact of
DOACs on routine and specialized coagulation assays.
Assays for anti-Xa or anti-IIa activity are the preferred
methods when quantitative information is useful,
although the situations in which to test for DOAC levels
are still debated. Different reagent sensitivities and vari-
abilities in laboratory calibrations impact assay results.
International calibration standards for all specific tests
for each DOAC are needed to reduce the inter-laboratory
variability and allow inter-study comparisons. The impact
of the DOACs on hemostasis testing may cause false-
positive or false-negative results; however, these can be
minimized by using specific assays and collecting blood
samples at trough concentrations. Finally, prospective
clinical trials are needed to validate the safety and efficacy
of proposed laboratory thresholds in relation to clinical
decisions. We offer recommendations on the tests to use
for measuring DOACs and practical guidance on labora-
tory testing to help patient management and avoid diag-
nostic errors.
Keywords: apixaban; dabigatran; edoxaban; laboratory
testing; practical management; rivaroxaban.
Introduction
The direct oral anticoagulants (DOACs; apixaban, betrix-
aban [not discussed in this review], dabigatran etexilate,
edoxaban and rivaroxaban) have become widely used
since their approval in several thromboembolic disorders,
including the treatment and secondary prevention of
recurrent venous thromboembolism (VTE) and the pre-
vention of stroke in patients with non-valvular atrial fib-
rillation (NVAF). These agents are administered as either
once-daily (od) or twice-daily (bid) fixed-dose regimens,
with dosage determined mainly by indication, age and/or
creatinine clearance, body weight, and the use of con-
comitant drugs [1–4].
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The DOACs exhibit more predictable pharmacokinetic
and pharmacodynamic profiles than vitamin K antago-
nists (VKAs); consequently, routine coagulation monitor-
ing is not required [5]. However, assessment of drug
exposure and its anticoagulant effect may be helpful in
certain clinical situations such as detection of drug accu-
mulation in acute renal/liver failure or overdose, assessing
anticoagulant activity in patients with bleeding or throm-
bosis, planning the timing of urgent surgery or interven-
tion, special patient characteristics such as obesity or
gastrointestinal malabsorption, determining the suitability
for thrombolytic therapy for acute ischemic stroke or
guiding the physician in the administration of reversal
agents [6,7]. The different circumstances for laboratory
testing, and the clinical relevance of such testing, remain
debated, particularly with regard to the interpretation of
test results and potential clinical implications.
In addition, because of their modes of action, DOACs
affect commonly used global coagulation assays [8–10]
and therefore influence coagulation function testing (e.g.
for thrombophilia or lupus anticoagulant). As DOAC use
continues to increase, it is also important to highlight
their impact on coagulation testing.
What test to use to determine the presence of DOACs
and their plasma concentrations?
The laboratory medicine specialist and clinician should
collaborate to establish an institutional protocol on when
and how to test DOACs, to guide the choice of the test
based on what information the clinician needs, and
to provide a multidisciplinary approach in its interpreta-
tion [8].
General considerations
The advantages and drawbacks of coagulation tests that
could be used to estimate plasma concentrations of the
DOACs or the relative intensity of anticoagulation are
summarized in Table 1. It may be noted that one impor-
tant parameter, the turnaround time (TAT), defined as
time from registration of the blood sample in the labora-
tory to first result communicated (including centrifugation
and analyses [reconstitution of the reagents when lyophi-
lized, preparation of calibration curve, validation of con-
trol plasma and sample analysis/validation]), is subject to
ongoing improvements (e.g. reduction of centrifugation
times and implementation of specific tests on a 24/7 basis).
To illustrate the feasibility of this, a recent study in patients
with acute stroke showed a median TAT of 34 min when
specific assays are routinely implemented [11].
Interpretation of the coagulation test results should
take account of the likely DOAC plasma concentration
range (Fig. 2), the timing of the last dose, the test
reagents and underlying pathologies that can influence PT
and APTT prolongation [12].
Direct thrombin inhibitor
Dabigatran The peak plasma concentration (CMAX) and
maximal anticoagulant effect of dabigatran is achieved
within 3 h after oral dosing [2]. The activated partial
thromboplastin time (APTT) can provide a qualitative
assessment of dabigatran activity, but the sensitivity
depends on the reagent and the coagulometer, which
complicates the interpretation of the results (Fig. 1) [8].
Most patients treated with dabigatran etexilate will pre-
sent with a prolonged APTT (ratio > 1.2; [APTT of the
patient]/[reference1 APTT]). A normal APTT excludes
above on-therapy levels of dabigatran but does not
exclude the presence of dabigatran in the on-therapy
range (Figs. 1 and 2) [13]. Conversely, a normal thrombin
time (TT) excludes the presence of dabigatran with a high
negative predictive value [14–16]. On the other hand, a
prolonged thrombin time could suggest either the pres-
ence of clinically relevant or trivial levels of dabigatran
because the TT is sensitive to dabigatran.
Specific tests are therefore required and the commer-
cially available diluted thrombin times (dTTs) that use
dabigatran calibrators can accurately determine dabiga-
tran level as they display a direct linear relationship with
drug concentration and a good accuracy in the 50–
500 ng mL1 concentration range [13]. For lower concen-
trations, an adapted procedure is proposed for some
dTTs (i.e. the Hemoclot Thrombin Inhibitor LOW,
Hyphen BioMed, Neuville sur-Oise, France, which uses a
lower dilution of the sample and incorporates a standard
at 0 ng mL1 in the calibration curve) (Fig. 2) [14]. On
the other hand, other dTT assays (i.e. the HemoSIL
Direct thrombin inhibitor (DTI), Instrumentation Labo-
ratory, Bedford, MA, USA) are accurate within a broader
range of concentration (from < 50 to 500 ng mL1) with-
out requiring different methodologies and calibration
curves.
Ecarin-based assays provide a direct measure of dabi-
gatran activity. Of these, even if currently recommended
in the European Summary of Product Characteristics
(EU-SmPC) [2], the ecarin clotting time (ECT) assay is
not readily available or useful in the absence of specific
kits and standards (i.e. standardization of the concentra-
tion of ecarin in the test), is not approved by regulatory
bodies (i.e. CE-marked or FDA 510k approved) in this
application and is therefore not recommended [17]. How-
ever, the STA-ECA-II (Diagnostica Stago, Asnie`re-sur-
Seine, France), an ecarin-based chromogenic assay, can
accurately assess dabigatran plasma concentrations in the
low (< 50 ng mL1) and the normal range (from 50 to
500 ng mL1; in this context, the term ‘normal range’ is
used as an analytical terminology to mention that there is
a normal calibration curve that is applicable from 50 to
1ReferenceAPTT/PTis theAPTT/PTofanormalpooledplasma(as in
Figure1)orthemeanAPTT/PTofatleast20normalsubjects.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
2 J. Douxfils et al
500 ng mL1, in opposition to the ‘low range’, which
requires adjusted calibration with some assays to assess
plasma level below 50 ng mL1; 50–500 ng mL1 does
not correspond to the on-therapy ranges, which are
depicted in Fig. 2). Importantly, ecarin assays are not
sensitive to heparins, which may be valuable in the case
of concomitant heparin administration (i.e. switching
therapy from heparins to dabigatran etexilate or vice
versa) [14]. A chromogenic anti-IIa assay has also been
proposed but requires further validations [18].
Direct factor Xa inhibitors
Apixaban, edoxaban and rivaroxaban The maximal
effect of apixaban and rivaroxaban is reached 3 h after
the drug intake, whereas 2 h are needed for edoxaban
[3,19]. Among the DOACs, rivaroxaban shows the stron-
gest effect on prothrombin time (PT), followed by edoxa-
ban and then apixaban, although different PT reagents
show variations in their sensitivities towards these drugs
[20,21]. Thus, as stated above, the establishment of an
Table 1 Characteristics of coagulation tests for estimating plasma concentrations of direct oral anticoagulants or their relative intensity of anti-
coagulation*
Drugs
Laboratory
tests Utility/interpretation Availability
Dependence
of the
reagent
Dabigatran APTT* Interpretation:
Normal APTT excludes above on-therapy dabigatran levels but
does not exclude the presence of dabigatran in the on-therapy
range
24/7, all laboratories Yes
TT Interpretation:
Normal TT excludes the presence of dabigatran. A prolonged TT
could suggest either the presence of clinically relevant or trivial
levels of dabigatran.
24/7, all laboratories Yes
dTT Interpretation:
Based on plasma concentration estimation in relation to the
clinical context.
Note: Some methodologies (i.e. the Hemoclot Thrombin
Inhibitors (HTI)) require specific calibrators for plasma
concentrations < 50 ng mL1
Can be implemented
with all
coagulometers
No
ECA Interpretation:
Based on plasma concentration estimation in relation to the
clinical context
Can be implemented
with all
coagulometers
No
Rivaroxaban
(Edoxaban)
PT* Interpretation:
Rivaroxaban: normal PT (with sensitive reagents) excludes above
on-therapy rivaroxaban levels but does not exclude the presence
of rivaroxaban in the on-therapy range.
Edoxaban: normal PT (with sensitive reagents) would exclude
above on-therapy edoxaban levels at peak but would not
exclude the presence of above on-therapy edoxaban at trough.
24/7, all laboratories Yes
Rivaroxaban
Apixaban
Edoxaban
Chromogenic
anti-Xa
assays*
Interpretation:
Based on plasma concentration estimation in relation to the
clinical context.
Note: Some methodologies (i.e. the Biophen Direct Factor Xa
Inhibitors (DiXaI)) require specific calibrators for plasma
concentrations < 30–50 ng mL1.
Note: If near to the LOQ, heparin or LMWH-calibrated
chromogenic anti-Xa assays can be used to rule out the presence
of clinically relevant direct FXa inhibitors.
Can be implemented
with all
coagulometers
No
Dabigatran
Rivaroxaban
Apixaban
Edoxaban
LC-MS/MS Interpretation:
Based on plasma concentration estimation in relation to the
clinical context
Requires trained staff;
only in specialized
laboratories
Not
applicable
dRVV-T
(DRVV-
DOAC)*
Interpretation:
Normal dRVV result can exclude DOAC concentrations
> 50 ng mL1.
Can be implemented
with all
coagulometers
Yes, but
< than PT
or APTT
APTT, activated partial thromboplastin time; dRVVT, diluted Russell’s viper venom time; dTT, dilute thrombin time; ECA, ecarin chro-
mogenic assay; ECT, ecarin clotting time; HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; LOD, limit of
detection; LOQ, limit of quantitation; PT, prothrombin time; TT, thrombin time. *None of these tests are able to discriminate between thera-
pies. Thrombin-specific tests can easily identify dabigatran because it is the only direct oral thrombin inhibitor, but also other direct thrombin
inhibitors such as argatroban or hirudin can influence them. For direct factor (F) Xa inhibitors, only the Biophen Direct Factor Xa Inhibitor
assay can discriminate between heparins and direct FXa inhibitors but cannot differentiate between direct FXa inhibitors. Mass spectrometry
is the only technique able to directly discriminate between therapies.
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institutional protocol by a multidisciplinary team able to
address the question of the sensitivity of the PT reagent is
mandatory.
Rivaroxaban prolongs PT in a concentration-dependent
manner. The sensitivity highly depends on the reagent used.
If more sensitive reagents (reagents are considered sensitive
when a low drug level (< 50 ng mL1) is sufficient to prolong
the assay above the normal reference range of the assay), such
as RecombiPlasTin2G (Instrumentation Laboratory) and
STA-NeoplastinCI +/NeoplastinR (Diagnostica Stago),
are used, PT can inform on the presence of rivaroxaban at
both trough (24 h after last intake) and peak (3 h after last
intake) levels and PT will be prolonged (ratio2 > 1.2; [PT of
the patient)/(reference PT]) in most patients. By contrast,
when less sensitive reagents such as Dade Innovin (a reagent
routinely used in many laboratories across Europe) are used,
PT is not affected (ratio < 1.2) by ‘on-therapy’ plasma
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Fig. 1. Impact of dabigatran on APTT, and of rivaroxaban, apixaban and edoxaban on PT: variations in reagent sensitivity. The dotted line
represents a ratio of 1.2, which is considered to be a relevant prolongation of the clotting time. APTT, activated partial thromboplastin time;
PT, prothrombin time.
2For PT, the ratio is different from the international normalized
ratio (INR), which is the same ratio corrected by an international
sensitivity index (ISI) specific to each batch of each reagent.
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VTE CMAX : 175 (117 – 275 ng mL–1) – mean (25th – 75th percentile)
NVAF CTROUGH : 44 (12 – 137 ng mL–1) – mean (5th – 95th percentile)
NVAF CMAX : 249 (184 – 343 ng mL–1) – mean (5th – 95th percentile)
VTE CTROUGH : 26 (6 – 87 ng mL–1) – mean (5th – 95th percentile)
VTE CMAX : 270 (189 – 419ng mL–1) – mean (5th – 95th percentile)
NVAF CTROUGH : 103 (41 – 230 ng mL–1) – median (5th – 95th percentile)
NVAF CMAX : 171 (91 – 321 ng mL–1) – median (5th – 95th percentile)
VTE CTROUGH : 63 (22 – 177 ng mL–1) – median (5th – 95th percentile)
VTE CMAX : 132 (59 – 302 ng mL–1) – median (5th – 95th percentile)
NVAF CTROUGH : 36 (19 – 62 ng mL–1) – median (IQR)
NVAF CMAX : 170 (125 – 245 ng mL–1) – median (1.5 × IQR)
VTE CTROUGH : 19 (10 – 39 ng mL–1) – median (IQR)
VTE CMAX : 234 (149 – 317 ng mL–1) – median (IQR)
APTT‡
APTT‡
APTT‡
APTT‡
Fig. 2. Laboratory testing of direct oral anticoagulants and expected plasma concentrations after therapeutic doses. Red and blue lines repre-
sent plasma concentrations at peak and trough in NVAF and VTE, respectively. Orange boxes represent ranges of applicability of the corre-
sponding test. †Depending on the dTT procedure used, the LOQ may be higher (i.e. 50 ng mL1 instead of 10 ng mL1). ‡This represents the
range of quantitation for sensitive reagents. Depending on the reagent, the sensitivity may be lower. Please refer to Fig. 1 for more details on
relevant testing. APTT, activated partial thromboplastin time; CMAX, maximum plasma concentration during the dosing interval;
CTROUGH, minimum plasma concentration during the dosing interval; dTT, diluted thrombin time; ECA, ecarin chromogenic assay; IQR,
interquartile range; LOQ, limit of quantitation; NVAF, non-valvular atrial fibrillation; PT, prothrombin time; TT, thrombin time; VTE, venous
thromboembolism. Notes: (i) Data on plasma concentration were extracted from current SmPC for dabigatran etexilate and apixaban or
according to Mueck et al. [19] for rivaroxaban and to Ruff et al. [54], Weitz et al. [53] and Verhamme et al. [61] for edoxaban. (ii) For dabiga-
tran edoxaban, plasma concentration ranges are expressed as mean or median ( IQR) representing only 50% of the population studied (ex-
cept for edoxaban NVAF CMAX extracted from Weitz et al., for which the range represents 75% of the population). Thus, for all dabigatran
and edoxaban concentrations, the 5th to 95th percentile ranges are broader than the results expressed here.
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concentrations of rivaroxaban at trough and is prolonged (ra-
tio between 1.2 and 1.5) at peak (Fig. 1) [22].
For apixaban, depending on the reagent, PT may be
normal in the presence of on-therapy ( 200 ng mL1)
concentrations (Fig. 2). Therefore, PT is not recom-
mended for estimating plasma drug concentrations of
apixaban or assessing the relative intensity of anticoagula-
tion at on-therapy doses. One alternative is the dilute
Russell’s viper venom time (dRVVT, a test which acti-
vates FX and triggers the formation of the prothrombi-
nase complex), which may suggest the presence of
apixaban if the dRVVT is prolonged and the PT is nor-
mal [23]. However, this will not distinguish DOAC ther-
apy from non-specific inhibitors if performed in isolation.
For edoxaban, prolongation of PT and APTT reaches
peak within 2 h, but the modest effect and variability
make these assays unsuitable for routine clinical assess-
ment of the anticoagulant effect. Conversely, data from a
recent study suggest that PT can be informative for ruling
out excess edoxaban plasma concentrations at trough
(prior to the next dose) but this would require sensitive
reagents (i.e. TriniCLOT PT Excel S [TCoag], STA-
NeoplastinR [Fig. 1]). For most reagents, PT will be
prolonged (ratio > 1.2) only at peak levels. [21].
Dedicated anti-Xa chromogenic assays using specific apix-
aban, edoxaban or rivaroxaban calibrators are able to mea-
sure a wide range of plasma concentrations covering the
expected levels after therapeutic doses with results expressed
in ng/ml (Fig. 2) [24]. They are more robust than global
assays, but are influenced by heparins, so caution is advised
in the interpretation of the result in the case of switching/
bridging therapy. One chromogenic anti-Xa assay is not gen-
erally influenced by heparins: the BiophenDirect Factor Xa
Inhibitor (Hyphen BioMed) test [25]. However, it should
also be noted that the limit of quantitation of most specific
tests is around 30–50 ng mL1 and that adapted methodolo-
gies (i.e. as for the Hemoclot Thrombin Inhibitor LOW
[Hyphen BioMed] for dabigatran) are suggested to assess
plasma concentrations < 50 ng mL1. There is no accurate
assay available to assess low plasma concentrations in
patients switched to or from LMWH [26].
DOAC-calibrated chromogenic anti-Xa assays are not
currently available in all hospitals, although with the emer-
gence of liquid stable reagents and more routine use, they
could be made available for emergency situations
(Table 1). Non-dedicated anti-Xa chromogenic assays used
to monitor heparin therapy are able to reliably exclude the
presence of direct factor (F) Xa inhibitors but are affected
by a high inter-assay variability and thus should not be
used to quantify direct anti-Xa inhibitors [3,4,20].
When to measure direct oral anticoagulants and how to
interpret the results of the different assays?
Measurement of DOACs may be required in several situ-
ations such as bleeding, thrombosis, urgent invasive
procedures, to approve thrombolysis, to guide elective
procedures (in specific populations or when the elimina-
tion of the DOAC could be impaired), in the case of
overdose, or to ensure on-therapy levels in patients with
multiple factors that interfere with pharmacokinetics of
DOACs. Recommendations for test selection depend
upon the clinical indication and the required information
(i.e. accurate plasma measurement of drug levels or esti-
mation of anticoagulant effect).
Emergency situations: is a direct oral anticoagulant present
and how much?
Cases of emergent situations include bleeding, thrombo-
sis, urgent invasive procedures and thrombolysis. In all
these cases, physicians aimed to identify levels within or
above the on-therapy range (Fig. 2). Studies in the real-
world setting revealed that testing is useful if immediately
available in urgent clinical situations where assessment of
drug presence is judged to be needed [27,28].
Management of emergency situations where an urgent
invasive procedure is indicated requires a fine assessment
of the urgency of the situation and the hemostatic status
of the patient to guide the potential use of specific rever-
sal agents or non-specific pro-hemostatic factors. Guid-
ance has been given by the Subcommittee on Control of
Anticoagulation of the International Society on Throm-
bosis and Hemostasis (ISTH) on the use of specific anti-
dotes for the reversal of DOACs (e.g. idarucizumab and
Praxbind, Boehringer Ingelheim, Ingelheim am Rhein,
Germany, for reversing dabigatran’s effect or andex-
anet alpha for FXa inhibitors). According to this docu-
ment, a drug concentration > 30 ng mL1 in patients
requiring an urgent intervention associated with a high
risk of bleeding is likely to be sufficiently high to warrant
antidote administration, whereas in patients with serious
bleeding, antidote administration should be considered if
the drug concentration exceeds 50 ng mL1 [29]. How-
ever, delaying the intervention or the administration of
an antidote until normalization or availability of coagula-
tion test results may be detrimental in the case of life-
threatening bleeding (e.g. intracranial bleeding, or in
emergency surgery for life-threatening conditions such as
a ruptured aortic aneurysm) and neutralization of the
anticoagulant effect should not be delayed while awaiting
test results [29,30].
In other cases, the use of specific coagulation tests may
also help to document the correction of hemostasis after
administration of the antidote or to guide the clinician in
the use of the antidote [29].
In those requiring thrombolysis, plasma concentrations
of 10 (apixaban), 50 (dabigatran) and 100 (rivaroxaban)
ng/mL have been proposed as cut-offs for considering
intravenous (i.v.) thrombolysis with r-tPA in patients with
acute ischemic stroke after an individual risk–benefit
assessment [31]. According to a study in rivaroxaban
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patients, i.v. thrombolysis is recommended if the plasma
concentration is < 20 (or 30 ng mL1). When the plasma
level is between 20 and 100 ng mL1 i.v. thrombolysis can
be considered, whereas plasma concentrations > 100 ng/ml
preclude the possibility of performing i.v. thrombolysis
[32]. Patients with intracranial artery occlusion were rec-
ommended i.v. thrombolysis plus endovascular treatment
or endovascular treatment alone if plasma levels were
≤ 100 ng/mL or > 100 ng/mL, respectively. In this study,
determination of rivaroxaban plasma levels enabled i.v.
thrombolysis in one-third of patients taking rivaroxaban
who would otherwise be ineligible for acute treatment. In
addition, no bleedings were reported in this study including
114 rivaroxaban patients. This clearly justifies the setting
up of future studies to investigate this approach.
Elective perioperative setting: is a direct oral anticoagulant
still present?
A discussion regarding the 2015 American Society of
Regional Anesthesia and Pain Medicine guidelines sug-
gests that interruption of DOACs should be based not
only on their respective half-lives, but also on the residual
drug concentration [33–36]. Although routine monitoring
is not required in the perioperative setting, there is still
insufficient data to endorse the pharmacokinetic (PK)
strategy in all circumstances [37–39].
For elective procedures, routine monitoring is not
required in the majority of the cases if the clinician respects
the time windows according to the risk of the procedure as
stated in the SmPC or guidelines [1–4,40]. However, some
patients (e.g. patients with multiple factors that interfere
with the pharmacokinetics of DOACs) or cases where the
time window is unsure could benefit from a laboratory
approach, especially for interventions associated with a
high bleeding risk (e.g. neuraxial procedure) that require
minimal to no anticoagulant effect at the time of the proce-
dure. Indeed, the empirical treatment cessation of 1–3 days
before the intervention, as suggested in the EU-SmPC and
in the Food and Drug Administration (FDA) Label Infor-
mation, revealed plasma concentrations of > 30 ng mL1
at least for dabigatran etexilate and rivaroxaban [41–43].
However, a recent prospective multicenter study confirmed
that a last DOAC intake 3 days before a procedure resulted
in minimal (< 30 ng mL1) pre-procedural anticoagulant
effect for almost all patients. Moderate renal impairment,
especially in dabigatran-treated patients, and the use of
antiarrhythmics in anti-Xa-treated patients should result in
a longer DOAC interruption [44]. Yet, the proposed cut-off
level of < 30 ng mL1 is still a matter of debate [37–39].
Thus, in anticipation of prospective clinical studies
designed to address this issue, the ability to measure drugs
levels may help to guide the timing of invasive procedures
in special circumstances.
To accurately measure low plasma drug concentrations
in the perioperative setting, specific tests calibrated for the
assessment of low plasma concentrations (i.e.
< 50 ng mL1) are required. For dabigatran, APTT is not
recommended, even in conjunction with PT [13,16]. Some
dTT tests are suitable for the low range without procedural
modifications (e.g. HemosILDTI and STA-ECA II);
others require a dedicated test (e.g. Hemoclot Thrombin
Inhibitor LOW). [14] If specific tests are not available, a
normal TT excludes the presence of dabigatran [15,16]. For
direct FXa inhibitors, PT is not sufficiently sensitive and
even in conjunction with the APTT, it cannot rule out the
presence of clinically relevant rivaroxaban levels [16]. Thus,
DOAC-calibrated anti-Xa chromogenic assays, using
appropriate calibrators and controls, have to be used to
ensure a reliable assessment of the residual activity of the
direct FXa inhibitor [26]. If not available, a heparin-cali-
brated anti-Xa chromogenic assay can be used to rule out
the presence of clinically relevant levels of a direct FXa
inhibitor but each laboratory should assess the sensitivity
of their respective heparin assay/calibrator systems for the
different direct FXa inhibitors using commercially avail-
able direct FXa inhibitors [20,45].
Impact of direct oral anticoagulants on coagulation
function assessments
Because of their modes of action, DOACs also interfere with
diagnostic tests for thrombophilia or bleeding disorders.
Prothrombin time (and the derived INR) and the
APTT are both influenced by DOACs. Depending on the
reagents, the coagulometer and the DOAC used by
the patient, the sensitivity of the PT/INR and the APTT
may vary (Fig. 1). Hence, a prolonged PT and/or APTT
in a patient with known DOAC exposure should be
expected and is likely to be drug related. However, physi-
cians should keep in mind that PT or APTT may be pro-
longed due to other causes than DOAC presence, such as
vitamin K deficiency, antibiotic use (which may impact
intestinal flora and the consequent vitamin K synthesis),
lipoglycopeptide antibiotics use (which may interfere with
phospholipids included in the reagent), lupus anticoagu-
lant, compromised liver function, dys-/a-fibrinogenemia
or consumption coagulopathy (such as disseminated
intravascular coagulation [DIC]) [46].
For thrombophilia testing, assays such as activated pro-
tein C (APC) resistance, antithrombin (AT), protein C,
protein S, lupus anticoagulant and clotting factor assays,
may be required. In these cases, testing should be per-
formed preferably at CTROUGH (i.e. 12 or 24 h after the last
drug intake for bid and od, respectively) even if interfer-
ences are still possible, depending on the sensitivity of the
test and the DOAC [47]. In the light of the possibility of
invalid results, the real need for these tests should be care-
fully evaluated in patients on DOAC treatment.
In cases of bleeding diathesis or DIC, specific tests such
as fibrinogen (Clauss and PT-derived method [dFib]), TT,
clotting factor activity and reptilase time may also be
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used. Again, it is of particular importance for clinicians
and laboratories to be aware of whether and how these
tests may be influenced by DOACs. DOACs do not inter-
fere with immunoassays and reptilase time but DOAC
therapy may affect D-dimer levels.
Thus, physicians should be aware that false-positive or
false-negative results are possible in patients receiving
DOACs and can lead to diagnostic errors. There are assays
unaffected by the DOACs that can be used for coagulation
function testing in these patients. If the DOAC-insensitive
assays cannot be used, missing one (for od dosing) or two
(for bid dosing) doses could be considered to minimize the
impact of residual DOACs on testing.
Some diagnostic companies are currently developing
strategies to make these tests insensitive to the DOACs or
to remove the DOACs from the blood before testing.
Finally, the clinician must inform the laboratory of the
drug currently taken by the patient and the expected
CTROUGH and CMAX, or the timing of the dose relative to
blood sampling. Table 2 summarizes the impact of
DOACs on the main coagulation function assays [21,48].
Discussion and conclusions
A wealth of knowledge has emerged over the last
5 years on testing DOAC levels. Although routine
assessment of the intensity of anticoagulation is not
required with these drugs, several situations may require
the use of coagulation testing [49]. Guideline recommen-
dations and consensus documents on laboratory testing
of the DOACs are generally consistent and provide clear
guidance for clinicians [8,50,51]. Specific tests have
emerged as the most suitable solution for the determina-
tion of DOAC plasma concentrations and may be used
in emergency situations with a turnaround time around
30 min. Studies are ongoing to further reduce this turn
around time or to implement point-of-care tests [52].
The cost of these specific tests has also been questioned.
They are more expensive than PT/APTT, but if one con-
siders that their use will be restricted to special situa-
tions, it is likely that the burden for health systems will
be lower than that presently incurred in managing
patients on VKAs.
Nevertheless, although determination of DOAC plasma
concentrations is now feasible, thresholds are yet to be
validated to ensure that clinical decisions based on labo-
ratory thresholds guarantee the optimal balance between
avoiding bleeding and preventing thrombosis. Expert soci-
eties have proposed algorithms and/or thresholds for clin-
ical situations based on extrapolation from
pharmacokinetic studies, which need to be validated in
prospective studies specifically designed for that purpose.
Table 2 Interference of direct oral anticoagulants with various coagulation assays
Test Dabigatran Rivaroxaban Apixaban Edoxaban Notes
PT-based measurements of
clotting factors/inhibitors
↓ ↓↓/↓↓↓ ↓/↓↓ ↓↓ • All factors affected
• Most sensitive to rivaroxaban
• Depends on the reagent
APTT-based measurements of
clotting factors/inhibitors
↓↓↓ ↓↓ ↓/↓↓ ↓/↓↓ • All factors affected
• Most sensitive to dabigatran
• Depends on the reagent
• Rivaroxaban also interferes with one-stage and chro-
mogenic factor (F) VIII:C assays
• Clotting assays based on activation of coagulation at
prothrombinase level unaffected by FXa inhibitors
Lupus anticoagulant: dRVVT ↑/↑↑ ↑/↑↑ –/↑ ↑ • False positives due to high screen/confirmation assay
ratios
• Taipan snake venom time and ECT time: alternative
assays in rivaroxaban-treated patients
• DOACs do not affect ELISA-based antiphospholipid
assays
APCR ↑ ↑ ↑ ↑ • APTT-based assays mostly affected
• Factor V Leiden APTT-based assay generally satisfac-
tory for apixaban-treated patients•
No interference of rivaroxaban with Pefakit APCR
Factor V Leiden
Protein C activity –/↑ –/↑ –/↑ –/↑ • Chromogenic assays: unaffected
• Antigen-based assays: unaffected
• Clot-based assays: affected
Protein S activity –/↑ –/↑ –/↑ –/↑ • Antigen-based assay: unaffected
• Clot-based: affected
Antithrombin activity –/↑ –/↑ –/↑ –/↑ • Anti-thrombin-based assays affected by dabigatran
• Anti-FXa-based assays affected by the FXa inhibitors
Abbreviations: ↓ to ↓↓↓, reduction; ↑ to ↑↑, increase; –, no effect; APCR, activated protein C resistance; APTT, activated partial thromboplastin
time; dRVVT, diluted Russell’s viper venom time; PT, prothrombin time.
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Indeed, there is currently no consensus on a therapeutic
range for these drugs even if some information can be
extracted from phase 2–3 clinical trials on the ‘on-ther-
apy’ range [2,3,19,53,54]. Publications [5,54,55] and/or
data from regulators [56,57] showed association between
plasma concentrations and bleeding risk but clear cut-offs
(i.e. evidence-based thresholds for antidote administra-
tion, risk of (perioperative) bleeding or eligibility for
thrombolysis) are not yet established for all DOACs for
the different clinical situations physicians may be facing.
Given the widespread use of DOACs, well-designed
prospective studies are required to support these prelimi-
nary proposals on the management of patients in the
periprocedural setting, for both elective and urgent proce-
dures. Appropriate strategies to guide the administration
and monitor the effect of reversal agents should also be
further investigated.
Studies in the real-world setting evaluating how drug
level testing is currently used in clinical practice
revealed that, to date, there is little urgency to make
the tests widely available for routine use outside of the
acute settings discussed above [27,28]. However, specific
populations, such as patients with a history of bleeding,
patients on polypharmacy with expected drug–drug
interactions, patients on immunomodulatory drugs,
those with extremes of bodyweight or gastrointestinal
malabsorption, patients with liver and/or renal dysfunc-
tion or those with multiple interfering factors, should
be further studied. To illustrate this, approximately 12–
13% of the patients demonstrated plasma concentra-
tions above the 95th percentile observed in phase-3 clin-
ical trials in a study assessing the interpatient variation
of apixaban and rivaroxaban in the routine care setting.
Drug levels also tend to be more variable (50 to 60-
fold interpatient variation) than predicted [58]. The high
inter-individual variability, the numerous factors inter-
fering with the pharmacokinetics and the dose–response
relationship observed in phase-3 studies [5,54,55], sug-
gest that the benefit–risk balance could be improved by
a proper dose titration, which could be guided by
determination of the response at the individual level in
selected patients. Such an approach has been suggested
by some manufacturers [59] and evidence demonstrated
that trough plasma levels (for edoxaban and dabiga-
tran), PT prolongation (for rivaroxaban) and AUC (for
apixaban) are all linked with bleeding risk [5]. Reports
of unexpected low plasma levels linked with throm-
boembolic events also suggest that more frequent mea-
surements may add value in the routine care setting
[60]. However, there are to date no clearly established
therapeutic ranges and for a given DOAC it is difficult
to titrate the dose using registered doses. Furthermore,
the effectiveness of such an approach has to be con-
firmed by clinical data [5].
Importantly, in the elective setting, recording of the
time between the last dose of DOAC and the blood
sampling is required for all coagulation assays in DOAC-
treated patients. Laboratories should also know the sensi-
tivity of their own reagent/coagulometer combinations.
Patients’ samples are preferred to in vitro experiments to
determine this sensitivity. Thus, there is an urgent need to
develop international standards for each DOAC compa-
rable to those for thromboplastin and heparin. This will
improve the inter-laboratory reproducibility for all speci-
fic tests and allow direct comparisons between studies in
order to develop and implement international guidelines
for the optimal management of patients treated with
DOACs.
Beside these strategies that aim to improve the safe use
of DOACs, the influence of DOACs on coagulation func-
tion testing or hemostasis diagnostic tests has also to be
clearly understood.
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